Archive for September, 2022

Joseph E. Sullivan, MD: Hello, and thank you for joining this NeurologyLive Cure Connections program titled Dravet Syndrome and Lennox-Gastaut Syndrome: Perspectives from the Patient Journey. Dravet syndrome is a rare and severe form of epilepsy that begins in infancy and continues throughout the lifetime. It is characterized by frequent often prolonged seizures that can be provoked by fever and may affect one side of the body. The majority of patients with Dravet Syndrome have pathogenic variants in the SCN1A gene.

Lennox-Gastaut Syndrome, often abbreviated as LGS, is another epilepsy syndrome that presents in childhood and persists throughout adolescence and adult years. Patients often experience multiple types of seizures, including stiffening of the body or temporary loss of muscle tone and consciousness, both of which often result in a fall. LGS can be caused by a variety of underlying conditions. In many cases, no cause can be identified.

My name is Dr. Joseph Sullivan, and I'll be your host today. I am a pediatric neurologist at the University of California, San Francisco Pediatric Epilepsy Center in San Francisco, California. I'm joined today by a colleague and friend Dr. Kelly Knupp, who's a pediatric neurologist at the University of Colorado School of Medicine in Aurora, Colorado. We are also joined by Mary Anne Meskis, also a friend and colleague, who is the founding member of the Dravet Syndrome Foundation, and her son has Dravet Syndrome. And lastly, we are joined by Dr. Tracy Dixon-Salazar, also a colleague and friend, who is executive director of the LGS Foundation; Dr. Dixon-Salazar is a neuroscientist and geneticists, and her daughter has LGS. Thank you all for joining me today; it's great to see you all. Let's get started with our program.

Our first section is going to be on Dravet Syndrome, and I really want to first start out with an overview, and how we start to suspect the diagnosis. Then, we will start to get into more of the details of why this is a syndrome, why it's more than just seizures, and how all these different aspects of the syndrome have an impact on quality of life. Kelly, maybe you can just start us off by giving an overview of Dravet Syndrome, how common it is, and the early symptoms and signs that we should be aware of.

Kelly Knupp, MD: Dravet Syndrome is a developmental epileptic encephalopathy that usually starts in the first year of life. It is most commonly characterized by seizures, of which there can be of multiple types, many of which are provoked by changes in temperature. We also see intellectual impairment that may actually be more apparent as children get older, which I think is really important when we're thinking about diagnosis, because we may not see that component early on. We can also see a progressive gait disorder, as well as behavioral disorders and a number of other comorbidities.

One of the characteristics of this syndrome is that it's often associated with a pathogenic variant in a gene called SCN1A. The vast majority of children do have one of those genetic diagnoses, but not all children. That's important to keep in mind, as well that there's a clinical syndrome, but we may not find a genetic mutation that goes along with it. It is also important to know that there are some children who have a pathogenic variant in SCN1A, who don't actually have Dravet syndrome. It's important to look for both of those things: the clinical syndrome as well as the gene mutation. Initially, we thought this wasn't very common, that it was present in about one in 40,000 children. Some recent data suggest that it's more common than that, perhaps about one in 15,000. It is something that we see in most practices, and I worry when people tell me that they haven't seen Dravet Syndrome in their practice, because I think they're probably missing it.

Joseph E. Sullivan, MD: Absolutely. We are of similar age and trained at similar times. When I was in training, I probably saw one child with Dravet Syndrome, which means we missed a lot of them. Its almost embarrassing, but you can see how it happens. We are told as pediatricians that febrile seizures are common and many of these kids are told not to worry about it. Could you go into a little bit more detail? In 2002, with everything that we know, when should we not be thinking this is just a febrile seizure?

Kelly Knupp, MD: I follow a child in my practice, and I remember having a conversation with this childs mom about how common febrile seizures were. I felt really comfortable that this was febrile seizures, and, in the end, it was not. Many of us have had that experience. In my mind, any child who's had a prolonged febrile seizure, particularly if it's one side shaking more than the other a hemiconvulsive seizure, we should think about doing genetic testing. For any child who's had 2 or more febrile seizures, if one of them has been prolonged, we need to think about doing genetic testing. I'm on the fence about the children who have had 2 simple febrile seizures and otherwise are doing well, because we know that about one-third of children who have a first febrile seizure will go on to have a second febrile seizure. But, if there's something like a prolonged seizure, or a focal nature to the seizure, we have to consider doing genetic testing.

Joseph E. Sullivan, MD: Age is a factor, too. We're told that febrile seizures occur at six months, if a patient has a simple febrile seizure at six months and then another simple febrile seizure at seven months, that's a worry to me.

Kelly Knupp, MD: That would start to make me a little anxious, too, I agree. Having them so close together would definitely worry me too.

Joseph E. Sullivan, MD: Classically, we used to think that Dravet syndrome only presented at less than one year of age. But now, with the ability to get genetic testing, we understand the evolution of a syndrome a little more, and it's clear that patients are presenting at a later age, although there still is kind of this sweet spot time, or age, when kids present.

Kelly Knupp, MD: Even for those older children, their parents usually are able to describe some sensitivity to change in temperature, which may not necessarily be a febrile illness, but can be other things, such as getting in and out of the bathtub. Whenever I hear somebody who describes their child having seizures when getting out of the bathtub, we should test for Dravet syndrome. Or for patients going in and out of the grocery store or Target, where that heat is blasting down on top of them, as soon as I hear that in history, I always need to look closer. Genetic testing for most of our patients in this age group is so readily available, even if insurance doesn't cover it. We have programs like Behind the Seizure, where it is relatively straightforward to get genetic testing in this cohort. Unfortunately, that doesn't help our older patients and adults, where this history may be difficult to tease out.

Transcript Edited for Clarity

Visit link:
Overview and Prevalence of Dravet Syndrome - Contemporary Pediatrics

Kristin Beasley is descended from some of the Big Horn Basins first settlers.

My ancestors were tough I come from a strong heritage, she said. It takes grit to settle a sagebrush area into a town. My family still lives in Emblem and Burlington.

It also takes toughness and grit to live with breast cancer.

Beasley was diagnosed with stage 4 breast cancer in 2019 and has since beat the cancer into remission while continuing to work, be a mother and a wife.

Now shes part of a campaign for Cody Regional Health. It was at CRHs Big Horn Basin Cancer Center where she got to ring the bell signifying the end of her tough treatments there, although it was not the end of the struggle, just a roadblock in a survivors journey.

There is a lot of fear and anxiety, she saidlast fall during a break in her workday at the Department of Family Services. And I juggle a lot work, kids, a monthly blood draw and doctor appointments. But I choose to be positive. There has been a lot of prayer and faith. A lot of friends supporting me. A lot of faith.

My story isnt over. And I choose to live and love while I can.

Cancer survivors often write stories about the process and their thoughts. This is Beasleys story:

I felt a lump and finally went to the doctor. I had a mammogram and ultrasound, followed by a biopsy in December of 2019. The results of my biopsy came back on a Monday afternoon. My husband and I met with the doctor on Tuesday to discuss options and I was in the O.R. having a lumpectomy on Wednesday. The margins of the lumpectomy werent completely clear, so I opted to have a complete mastectomy. Between surgeries, my family and I were able to go on a wonderful vacation (that was already planned) to Kennedy Space Center and Disney World at the beginning of January 2020. I came back and really started this journey. I had a mastectomy in January 2020. I finally met with an oncologist. We chose the chemo regimen I was going to have. I finally convinced her to do a CT scan. That CT showed findings in my lymph nodes and sternum. I read the CT results and called my doctor because she didnt tell me about the findings in the sternum.

That weekend was horrible. Every test I had taken was showing something worse and worse. The feeling of being told you have stage 4 cancer, I cant even put into words. The fear of what will happen can be overpowering. Although I felt just fine, the tests kept saying this disease is progressed. At this point, I didnt know how fast this would progress, how long I would live if I would see my kids graduate from high school. I choose to focus on the positive and just keep going because otherwise the fear and anxiety becomes overpowering.

Through all this, although I was extremely scared, I felt calm. A calm I can only describe as Gods love and peace. That love and peace continue. It doesnt always make it easier, but I also know its going to be okay.

I quickly switched doctors to the Cancer Center. They got me in to see a doctor very quickly. I had a biopsy of the sternum which confirmed that breast cancer was indeed in my sternum. Since I was so young (I was 42 when I was diagnosed), we did genetic testing. This showed that I was BRCA 2 positive. Although I didnt realize I had a family history, my disease is genetic. My mother and both sisters have also had genetic testing and are also positive. Luckily they can monitor and take measures to not get this disease as I have.

My team of doctors and I decided to begin my treatment with radiation. A lot of cancer patients start with chemo and then have radiation. I had radiation in April of 2019. School had just shut down for Covid, and my fourth and sixth-grade daughters were doing home school. I was working full time, and going to my radiation appointments during my lunch hour. I would go home after work to be a mom and wife cleaning and cooking. All the while worrying about my disease and how it affects my kids and if treatment would be effective. I rang the Bell of radiation May 1, 2020. To me, instead of feeling like the end of my journey, it felt like the beginning. The radiation staff and Dr. Lord are amazing. They made a very uncomfortable, hard situation tolerable.

After I finished radiation my ovaries were completely shut down. This needed to happen because my cancer is hormonal. I couldnt have a hysterectomy because elective surgeries were not happening at that point. I was put into instant menopause. Complete with hot flashes, hormonal rages (I would completely lose it on my poor dog laying on my bed at night) and always sleeping hot. I also began Ibrance daily oral chemo, and an infusion for bone strength once a month. I continue that regimen. I go to work, church, kids activities and live with this disease. Cancer and the treatment affect everyone differently. I havent missed work because I was sick Somehow I have pushed through.

I had a hysterectomy a year ago in October 2020. This surgery was hard to recover from. I took one week off work and went back part-time the next week. Then I was back full time every day. But it took a long time to get my energy back. Now to monitor my disease I have a PET scan every six months (Ive had three so far), a CT scan once a year and an MRI every year. I also see a dermatologist for a full body skin check. The BRCA 2 gene carries an increased risk for breast, ovarian, pancreatic and melanoma.

The doctors and nurses at the cancer center are amazing. Many I know and are friends with. Their love and support have helped get me through this. Since I walked into that building, I knew they had my back. In fact, one of the nurses is my friend. When she heard about my experience with my first doctor, she called me and told me I needed to be at the cancer center. They could take care of me, and I needed to switch doctors. Her concern for me is a major reason I switched to the cancer center. ALL the staff doctors, nurses and front desk are amazing. They really care about you, and I know they absolutely want to give me the best care they can.

The quotes I live by: Keep trying, keep trusting, keep believing. Heaven is cheering you on today, tomorrow, and forever. Jeffrey R Holland and You never know how strong you are until being strong is the only choice you have. - Bob Marley

Visit link:
'It takes toughness and grit' Beasley shares on her breast cancer battle, survivor's journey - Cody Enterprise

One of the tests is analyzed in China and both mother and fetal DNA might be accessed by the Chinese government.

If the Chinese authorities really want to, they will get access to the genetic data. This is the general relationship between Chinese companies and the state. You cannot know what happens to your own and the unborn childs DNA, Mette Halskov Hansen, professor in Chinese Studies at the University of Oslo, tells the Norwegian Biotechnology Advisory Boards journal.

In Norway, genetic testing types are more limited than Denmark and Sweden.

The possibility of Chinese authorities access to Norwegian DNA comes from the fact that one of the NIPT tests which are broadly used in Denmark and Sweden, Nifty, has been developed and analyzed by the Chinese company BGI.

BGI writes that Chinese authorities are given access to genetic data if national security considerations dictate.

Source: https://sciencenorway.no/china-dna-foetus/the-norwegian-consumer-council-warns-that-norwegian-dna-is-being-sent-to-china/2068572

View original post here:
Warning to pregnant Norwegian women as their DNA can be accessed by Chinese authorities - ScandAsia.com

DUBLIN--(BUSINESS WIRE)--The "Global Molecular Diagnostics Devices And Equipment Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

The global molecular diagnostics devices and equipment market is expected to grow from $24.19 billion in 2021 to $27.91 billion in 2022 at a compound annual growth rate (CAGR) of 15.3%. The market is expected to grow to $46.87 billion in 2026 at a compound annual growth rate (CAGR) of 13.8%.

Major players in the molecular diagnostics devices (or) equipment market are Roche Ltd, Hologic, QIAGEN, Abbott, Danaher Corporation, Bio-Rad Laboratories, Siemens Healthcare, Becton Dickinson and Company, Cepheid Inc, and bioMerieux S.A.

The molecular diagnostics devices (or) equipment market consists of sales of molecular diagnostics devices and related services. Molecular diagnostics devices are used to diagnose infectious diseases and perform screening by detecting specific sequences in DNA or RNA at the molecular level. It helps doctors to prescribe more accurate therapeutic interventions in the early stages of a disease.

The main products of molecular diagnostics devices (or) equipment are instruments, reagents, and consumables. A reagent is a substance that is used for causing a chemical reaction. Reagents are used to indicate the presence of another substance.

The technologies involved are DNA (deoxyribonucleic acid) sequencing, polymerase chain reaction, isothermal nucleic acid amplification technology, transcription-mediated amplification (TMA), in situ hybridization, microarrays, mass spectrometry, and others (southern blotting, northern blotting, and electrophoresis).

The various applications are cancer, pharmacogenomics, genetic testing, infectious disease, prenatal, neurological disease, and cardiovascular disease that are used by various end-users such as diagnostic laboratories, hospitals, and others (nursing homes, blood banks, point of care).

Asia Pacific was the largest region in the molecular diagnostics devices (or) equipment market in 2021. Western Europe was the second largest market in molecular diagnostics devices (or) equipment market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The growth in the molecular diagnostic devices and equipment market is attributed to factors such as the rapid rise in various bacterial and viral epidemics. The increase in the spread of diseases increases the demand for early and improved diagnostic methods.

To improve the technology to enable the early diagnosis of such diseases, the Government and different organizations extend their financial support towards the major key players of the industry. For example, according to the reports from Centres for Disease Control and Prevention (CDC) US, as of March 2019, 72 Zika virus disease cases were reported in U.S state and 148 Zika virus disease cases reported in US Territories.

Thus, the rise of such chronic diseases serves as a prime driver for the players in the industry to develop more accurate and sophisticated diagnostic devices and equipment. Following the increase in demand for early diagnosis of Zika virus, Co-Diagnostics, Inc. in February 2019 launched its first multi-disease molecular diagnostic test for dengue, chikungunya, and Zika.

The regulatory process involving the approval of molecular diagnostic tests is often slow. The lack of clear definition coupled with constant changes in the regulations is a challenge for companies developing these kits. In developing nations such as India and China lack of a well-defined regulatory framework negatively impacts the market, irrespective of the presence of a large population.

In the US market, because of the changes in the rules and regulations, the products already in the market may also be required to go through Food and Drug Administration (FDA)'s pre-marketing approval process. For example, CLIA (Clinical Laboratory Improvement Amendments Act) in the US certifies the validity of laboratory-based tests but it does not regulate the clinical validity of molecular diagnostic tests. This means that it does not control whether these results are clinically correct. This argument puts a restraint on the industry and opens an argument that FDA should play a greater role in overseeing laboratories.

The major players in the molecular diagnostic industry are focusing on developing automated solutions for devices and equipment used for molecular diagnostic processes. Automation of the process will help to enhance the productivity and consistency of the whole diagnostic process. Computerization of the diagnostic process gives reliable and efficient test results that manual testing by various experts does not.

The major players of the industry are using nanotechnology-based Oral Fluid Nano Sensor Test (OFNASET). The test uses a microfluidic-based nanosensor for the detection of oral cancer biomarkers in saliva. To keep up with the trend of automation and accuracy, Roche, created cobas connection modules (CCM) to improve scalability and sample-flow efficiency by allowing samples to automatically move between different systems and instruments. Thus, creating a fully automated workflow.

The molecular diagnostic devices in the US are approved by Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH). These diagnostics devices are generally approved with an accompanying assay, to evaluate their safety and effectiveness or substantial equivalence regarding the assays they run and the assay's defined performance parameters.

However, the same instruments do not require FDA approval or clearance when used for basic scientific research purposes. The European regulatory landscape has become more stringent and technically challenging for medical device companies.

The introduction of four different risk classes of diagnostic devices i.e. classes A-D. Class A refers to the lowest risk tests and class D refers to the highest risk test such as HIV testing, blood grouping, and prenatal testing. Most of the genetic testing is classed into class C. The products bearing a CE mark, European approved tests, are safe to use, and are in full compliance.

Key Topics Covered:

1. Executive Summary

2. Molecular Diagnostics Devices And Equipment Market Characteristics

3. Molecular Diagnostics Devices And Equipment Market Trends And Strategies

4. Impact Of COVID-19 On Molecular Diagnostics Devices And Equipment

5. Molecular Diagnostics Devices And Equipment Market Size And Growth

5.1. Global Molecular Diagnostics Devices And Equipment Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Molecular Diagnostics Devices And Equipment Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Molecular Diagnostics Devices And Equipment Market Segmentation

6.1. Global Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.2. Global Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.3. Global Molecular Diagnostics Devices And Equipment Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.4. Global Molecular Diagnostics Devices And Equipment Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7. Molecular Diagnostics Devices And Equipment Market Regional And Country Analysis

7.1. Global Molecular Diagnostics Devices And Equipment Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global Molecular Diagnostics Devices And Equipment Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Molecular Diagnostics Devices And Equipment Market

8.1. Asia-Pacific Molecular Diagnostics Devices And Equipment Market Overview

8.2. Asia-Pacific Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8.3. Asia-Pacific Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Molecular Diagnostics Devices And Equipment Market

9.1. China Molecular Diagnostics Devices And Equipment Market Overview

9.2. China Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

9.3. China Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Molecular Diagnostics Devices And Equipment Market

10.1. India Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

10.2. India Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Molecular Diagnostics Devices And Equipment Market

11.1. Japan Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11.2. Japan Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Molecular Diagnostics Devices And Equipment Market

12.1. Australia Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12.2. Australia Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Molecular Diagnostics Devices And Equipment Market

13.1. Indonesia Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13.2. Indonesia Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Molecular Diagnostics Devices And Equipment Market

14.1. South Korea Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14.2. South Korea Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Molecular Diagnostics Devices And Equipment Market

15.1. Western Europe Molecular Diagnostics Devices And Equipment Market Overview

15.2. Western Europe Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15.3. Western Europe Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Molecular Diagnostics Devices And Equipment Market

16.1. UK Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16.2. UK Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Molecular Diagnostics Devices And Equipment Market

17.1. Germany Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17.2. Germany Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Molecular Diagnostics Devices And Equipment Market

18.4. France Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18.5. France Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Molecular Diagnostics Devices And Equipment Market

19.1. Eastern Europe Molecular Diagnostics Devices And Equipment Market Overview

19.2. Eastern Europe Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19.3. Eastern Europe Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Molecular Diagnostics Devices And Equipment Market

20.1. Russia Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20.2. Russia Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Molecular Diagnostics Devices And Equipment Market

21.1. North America Molecular Diagnostics Devices And Equipment Market Overview

21.2. North America Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21.3. North America Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Molecular Diagnostics Devices And Equipment Market

22.1. USA Molecular Diagnostics Devices And Equipment Market Overview

22.2. USA Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22.3. USA Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Molecular Diagnostics Devices And Equipment Market

23.1. South America Molecular Diagnostics Devices And Equipment Market Overview

23.2. South America Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23.3. South America Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Molecular Diagnostics Devices And Equipment Market

24.1. Brazil Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24.2. Brazil Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Molecular Diagnostics Devices And Equipment Market

25.1. Middle East Molecular Diagnostics Devices And Equipment Market Overview

25.2. Middle East Molecular Diagnostics Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25.3. Middle East Molecular Diagnostics Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Link:
Global Molecular Diagnostics Devices and Equipment Market Report 2022: A $46.87 Billion Market in 2026 - Long-term Forecast to 2031 -...